

# SNAPSHOT OF INDIES (JMD) AS @ NOVEMBER 30, 2022

COMPANY PERFORMANCE

INPUT		BOARD OF DIRECTORS	
JSE Ticker:	INDIES (JMD)	Dr. Guna Muppuri	Dev Kumar Singh
Report Date:	11/30/22	Vishnu Muppuri	
Market of Listing	Retail	Mr. Lissant Mitchell	
Analysis Period (months):	12	Professor. Trevor Mccartney	
Start Date of Analysis Period:	12/05/21	Kevin Alexis Donaldson	

## COMPANY DESCRIPTION

Indies Pharma Jamaica Ltd produces and distributes specialty pharmaceutical products. The Company offers ointment, capsules, creams, nasal sprays, syrup, eye drops, injections, and tablets. INDIES serves patients in Jamaica. The Company now has approximately more than hundred drug presentations in the market.

KEY MANAGEMENT EXECUTIVES		
Chief Executive Officer	Dr. Guna Muppuri	
Chief Operating Officer	Vishnu Muppuri	

Cab Structure. %

47%

53%

100%

11.14% 21.06%

\$0.11 3.72%

**Overall Market** 

NA NA [\$.00 - \$.00] NA \$2.96

Reporting Currency		JMD		\$
Revenues	(\$'000)	\$941,155	Total Liabilities (\$'000)	\$1,020,152
Other Income	(\$'000)	(\$1,447)	Total Equity (\$'000)	\$1,144,973
5-Year Revenue CAGR	(\$'000)	8.09%	Total Assets (\$'000)	\$2,165,125
Operating Expenses	(\$'000)	\$363,412		
Efficiency Ratio		39%	Return on Assets	
Current Earnings	(\$'000)	\$241,131	Return on Equity	
Net Earnings Margin		25.62%		
EPS		\$0.181	Dividends Per Share	
Book Value Per Share		\$0.86	Dividend Yield (TTM)	
c		KET DATA		INDUSTRY MARKET DATA
Trading Currency		JMD		
Shares Outstanding		1,332,536,649	JMMB Sector Classification *	Retail
Close Price		\$2.96	Market Cap of Industry	NA
Market Capitalization		\$3,944,308,481	% of Sector Index	NA
Current P/E Ratio of INI	DIES (JMD)	16.36x		VALUATION METRICS
Current P/E Ratio of Sec	tor	NA	Implied Valuation <sub>P/E</sub>	
Current P/B Ratio		3.44x	Implied Valuation <sub>P/B</sub>	
Current P/B Ratio of Sec	ctor	NA	Implied Valuation Range	
7D Moving Average		\$2.75	Implied Valuation Average	
365D Moving Average		\$3.03	Current Price	
				NA
L		ICATORS		HISTORICAL PRICES & VOLUM
	-			

\$3.13

\$3.14

\$0.01

0.32%

1,332,536,649 158,780

\$473.628

MEDIUM

	NA
	HISTORICAL PRICES & VOLUMES
\$4.00	\$2.96
\$3.50 -	5,000,000
\$3.00	- Manuna was when Manuna and
\$2.50 -	4,000,000
\$2.00 -	- 3,000,000
\$1.50 -	2,000,000
\$1.00 -	
\$0.50 -	- 1,000,000
پیس <u>الیالا ہے۔</u> \$0.00	
12/05/21 12/13/21 12/13/21 12/21/21 12/22/22 01/14/22	00,1302 00,150
	VOLUME CLOSE PRICE

IW % Change	9.63%
IM % Change	4.59%
3M % Change	-5.13%
I2M % Change	-9.76%
5Y % Change	NA

SHARE PRICE MOMENTUM

### SHARE PRICE COMMENTARY Over the last 12 months, INDIES (JMD) has decreased by 10%. The Average Price (VWAP) of INDIES (JMD) over this period has been \$2.99. The stock traded as high as \$3.52 on January 03, 2022 and as low as \$2.56 on November 28, 2022.

# COMPANY NEWS

9-Sep-22	INDIES has submitted its unaudited financial statements for the third quarter ended July 30, 2022.	
14-Jun-22	INDIES has submitted its unaudited financial statements for the second quarter ended April 30, 2022.	
22-Apr-22	INDIES has declared an interim dividend of 11.3 cents (\$0.113) per share payable on May 26, 2022 to shareholders on record as at May 6, 2022. The ex-dividend date is May 5, 2022.	
13-Apr-22	INDIES has advised that the Annual General Meeting of the Company will be held at 10:30 a.m. on Friday, May 27, 2022 at the Indies Pharma Distribution Center, Bioprist HQ Building, IA Pimento Way, Freeport, Montego Bay, St. James.	
II-Apr-22	INDIES has advised that at a meeting of its Board of Directors to be held on Thursday, April 21, 2022, a dividend payment will be considered.	

<sup>1</sup> Company Performance metrics are calculated using trailing twelve (12) months financial data as at 7/31/2022

Disclaimer:

Current Bid

Current Ask

ID % Change

Bid Ask Spread, \$

Bid Ask Spread, %

Total Shares Outstanding

Liquidity Classification

Avg Daily Volume Traded, Trailing 12M Avg. Daily Value (\$) Traded, Trailing 12M

While JMMB®'s Proprietary Trading Portfolio may take positions in any of the above securities, these trading decisions are not necessarily guided by, nor do they influence, as to why these are our recommendations. All information contained herein is obtained by JMMB® from sources believed by it to be accurate and reliable. The Author of this report may or may not have an interest in the securities outlined. All opinions and estimates constitute the author's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR COMPLETENESS OF THIS REPORT IS GIVEN OR MADE BY JMMB® IN ANY FORM WHATSOEVER. All information contained herein is obtained by JMMB® Securities Limited from sources believed by it to be accurate and reliable. All opinions and estimates constitute the Analysi's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR Constitute the Analysi's judgment as of the date of the report. However, neither its accuracy and completeness NOR THE OPINIONS BASED THEREON ARE GUARANTEED. As such NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS OR COMPLETENESS OF THIS REPORT IS GIVEN OR MADE BY JMMB® IN ANY FORM WHATSOEVER.